Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
AOD-9604 (AOD) is a metabolic peptide, at the clinical trials stage in the published literature. Fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis without the growth-promoting effects of HGH.
Fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis without the growth-promoting effects of HGH.
| Research Status | Clinical trials |
|---|---|
| Half-Life | Unknown (short) |
| Administration | Subcutaneous injection |
| Doses Reported in Published Studies | 250-500 mcg |
Mimics the fat-burning portion of HGH without affecting IGF-1 or insulin. Stimulates lipolysis.
Fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis without the growth-promoting effects of HGH.
Mimics the fat-burning portion of HGH without affecting IGF-1 or insulin. Stimulates lipolysis.
AOD-9604 is at the following stage in the published literature: Clinical trials. All information is for research and educational purposes only.
Reported half-life: Unknown (short).
Reported administration route in the literature: Subcutaneous injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.